Relevium announces TSX-V conditional acceptance of BioGanix acquisition

Photo of author

By Ted Liu

Montreal (pcJ News Briefs) – Relevium Technologies Inc. (TSX-V: RLV: FSE: 6BX), a consolidator of e-commerce assets in Health and Wellness, has received conditional acceptance from the TSX Venture Exchange (TSX-V) regarding a binding letter of intent (LOI) to acquire the assets of BioGanix Limited, a privately- held nutraceutical company in Houston, Texas focused on heart, brain, digestive health and joint support products sold through primarily through e-commerce platforms.

“Management is working diligently in conjunction with its agent and the target on the concurrent financing and on the documentation necessary to meet the requirements of the TSX Venture Exchange. We remained fully engaged and look forward to a smooth process,” said Aurelio Useche, CEO of Relevium Technologies.

Relevium is focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.